Thyroid Profile in the First Three Months After Starting Treatment in Children with Newly Diagnosed Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Mar 11

PMID 36900289

Authors

Chantal A Lebbink

Cor van den Bos

Miranda P Dierselhuis

Marta Fiocco

Annemarie A Verrijn Stuart

Eef G W M Lentjes

Sabine L A Plasschaert

Wim J E Tissing

Hanneke M van Santen

Affiliations

Soon will be listed here.

Abstract

Background: Thyroid hormone anomalies during childhood might affect neurological development, school performance and quality of life, as well as daily energy, growth, body mass index and bone development. Thyroid dysfunction (hypo- or hyperthyroidism) may occur during childhood cancer treatment, although its prevalence is unknown. The thyroid profile may also change as a form of adaptation during illness, which is called euthyroid sick syndrome (ESS). In children with central hypothyroidism, a decline in FT4 of >20% has been shown to be clinically relevant. We aimed to quantify the percentage, severity and risk factors of a changing thyroid profile in the first three months of childhood cancer treatment.

Methods: In 284 children with newly diagnosed cancer, a prospective evaluation of the thyroid profile was performed at diagnosis and three months after starting treatment.

Results: Subclinical hypothyroidism was found in 8.2% and 2.9% of children and subclinical hyperthyroidism in 3.6% and in 0.7% of children at diagnosis and after three months, respectively. ESS was present in 1.5% of children after three months. In 28% of children, FT4 concentration decreased by ≥20%.

Conclusions: Children with cancer are at low risk of developing hypo- or hyperthyroidism in the first three months after starting treatment but may develop a significant decline in FT4 concentrations. Future studies are needed to investigate the clinical consequences thereof.

References

Ness K, Armstrong G, Kundu M, Wilson C, Tchkonia T, Kirkland J . Frailty in childhood cancer survivors. Cancer. 2014; 121(10):1540-7. PMC: 4424063. DOI: 10.1002/cncr.29211. View

Lebbink C, Waguespack S, van Santen H . Thyroid Dysfunction and Thyroid Cancer in Childhood Cancer Survivors: Prevalence, Surveillance and Management. Front Horm Res. 2021; 54:140-153. DOI: 10.1159/000513805. View

Reiter E, Lee P . Delayed puberty. Adolesc Med. 2002; 13(1):101-18, vii. View

van Santen H, Thonissen N, de Kraker J, Vulsma T . Changes in thyroid hormone state in children receiving chemotherapy. Clin Endocrinol (Oxf). 2005; 62(2):250-7. DOI: 10.1111/j.1365-2265.2005.02210.x. View

Brierre S, Kumari R, deBoisblanc B . The endocrine system during sepsis. Am J Med Sci. 2004; 328(4):238-47. DOI: 10.1097/00000441-200410000-00007. View

Xiu S, Mu Z, Zhao L, Sun L . Low free triiodothyronine levels are associated with risk of frailty in older adults with type 2 diabetes mellitus. Exp Gerontol. 2020; 138:111013. DOI: 10.1016/j.exger.2020.111013. View

Ferster A, Glinoer D, Van Vliet G, Otten J . Thyroid function during L-asparaginase therapy in children with acute lymphoblastic leukemia: difference between induction and late intensification. Am J Pediatr Hematol Oncol. 1992; 14(3):192-6. DOI: 10.1097/00043426-199208000-00002. View

Heidemann P, Stubbe P, Beck W . Transient secondary hypothyroidism and thyroxine binding globulin deficiency in leukemic children during polychemotherapy: an effect of L-asparaginase. Eur J Pediatr. 1981; 136(3):291-5. DOI: 10.1007/BF00442997. View

Arrigo T, Rulli I, Sferlazzas C, De Luca F . Pubertal development in cystic fibrosis: an overview. J Pediatr Endocrinol Metab. 2003; 16 Suppl 2:267-70. View

10.

Chao M, Schwartz J, Wechsler D, Thornburg C, Griffith K, Williams J . High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer. 2004; 44(5):441-8. DOI: 10.1002/pbc.20168. View

11.

Hokken-Koelega A, Saenger P, Cappa M, Greggio N . Unresolved problems concerning optimal therapy of puberty in children with chronic renal diseases. J Pediatr Endocrinol Metab. 2001; 14 Suppl 2:945-52. DOI: 10.1515/jpem-2001-s206. View

12.

van Iersel L, van Santen H, Potter B, Li Z, Conklin H, Zhang H . Clinical impact of hypothalamic-pituitary disorders after conformal radiation therapy for pediatric low-grade glioma or ependymoma. Pediatr Blood Cancer. 2020; 67(12):e28723. DOI: 10.1002/pbc.28723. View

13.

Re R, Kourides I, Ridgway E, Weintraub B, Maloof F . The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab. 1976; 43(2):338-46. DOI: 10.1210/jcem-43-2-338. View

14.

van Iersel L, Xu J, Potter B, Conklin H, Zhang H, Chemaitilly W . Clinical Importance of Free Thyroxine Concentration Decline After Radiotherapy for Pediatric and Adolescent Brain Tumors. J Clin Endocrinol Metab. 2019; 104(11):4998-5007. DOI: 10.1210/jc.2019-00539. View

15.

Van den Berghe G . Euthyroid sick syndrome. Curr Opin Anaesthesiol. 2006; 13(2):89-91. DOI: 10.1097/00001503-200004000-00001. View

16.

Fliers E, Boelen A . An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2020; 44(8):1597-1607. PMC: 8285315. DOI: 10.1007/s40618-020-01482-4. View

17.

Williams G . Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol. 2008; 20(6):784-94. DOI: 10.1111/j.1365-2826.2008.01733.x. View

18.

Narayanan K, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N . Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer. 2013; 60(7):1148-53. DOI: 10.1002/pbc.24397. View

19.

Weise K, Zaritsky A . Endocrine manifestations of critical illness in the child. Pediatr Clin North Am. 1987; 34(1):119-30. DOI: 10.1016/s0031-3955(16)36185-5. View

20.

Rodig N, McDermott K, Schneider M, Hotchkiss H, Yadin O, Seikaly M . Growth in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children Study. Pediatr Nephrol. 2014; 29(10):1987-95. PMC: 4470271. DOI: 10.1007/s00467-014-2812-9. View